CJC-1295 is a synthetic growth hormone-releasing hormone analogue designed to prolong stimulation of the growth hormone and IGF-1 axis. Early human studies confirm that a long-acting form can change those biomarkers for days, but they do not prove better recovery, body composition, sleep or anti-aging outcomes. Commercial naming is also unusually confusing: "CJC-1295," "CJC-1295 with DAC" and "CJC-1295 without DAC" may not describe the same substance. This guide explains what was actually studied, what remains unknown and why approval and product identity matter.
What is CJC-1295?
Natural growth hormone-releasing hormone, or GHRH, is produced in the hypothalamus and stimulates pituitary somatotroph cells to release growth hormone. CJC-1295 was engineered as a GHRH analogue. The best-known version includes a drug-affinity-complex, or DAC, group that covalently binds circulating albumin and markedly extends exposure.
That pharmacology separates it from short-acting sermorelin, which corresponds to the active 1-29 region of GHRH. It also differs from ipamorelin and other ghrelin-receptor agonists, which act through GHSR-1a rather than the GHRH receptor.
The distinction matters because a long-lived analogue creates a sustained biological signal. It should not be described as a simple substitute for a short physiological pulse.
Why "with DAC" and "without DAC" are not minor variants
The foundational human trials evaluated material described as long-acting CJC-1295. FDA's 2024 technical review concluded that this was most likely a DAC active moiety, but noted uncertainty about the exact form. The agency separately assessed CJC-1295 free base, acetate, DAC free base, DAC acetate and DAC trifluoroacetate.
Online sellers often use "CJC-1295 without DAC" for a shorter peptide also called modified GRF(1-29). That convention does not establish chemical identity, and findings from the albumin-binding compound should not be transferred to it.
| Feature | Long-acting CJC-1295 DAC studied in humans | Products labeled "CJC-1295 no DAC" |
|---|---|---|
| Albumin binding | Designed for covalent binding | Generally marketed as non-albumin-binding |
| Evidence | Two small randomized studies in healthy adults | No comparable published clinical program identified by FDA |
| Duration | Estimated half-life of 5.8 to 8.1 days in the 2006 study | Cannot be inferred from the DAC trial |
| Naming reliability | Exact salt/form was still unclear in the literature | Commercial terminology is inconsistent |
A certificate that only states "CJC-1295" leaves a clinically important question unanswered.
What did the human studies find?
In 2006, Teichman and colleagues reported two randomized, double-blind, placebo-controlled, dose-escalation studies in healthy adults aged 21 to 61. After a single exposure, mean growth hormone concentrations increased 2- to 10-fold for at least six days, while mean IGF-1 increased 1.5- to 3-fold for nine to eleven days. With repeat exposure, mean IGF-1 remained above baseline for up to 28 days.
A second analysis in healthy men found that growth hormone pulsatility persisted one week after CJC-1295, but trough growth hormone rose markedly. That observation helps describe endocrine behavior; it does not demonstrate a health benefit.
These studies answer a narrow pharmacology question: can a DAC form stimulate the GH/IGF-1 axis for an extended period? They do not establish:
- treatment of adult or pediatric growth hormone deficiency;
- increased strength, improved recovery or reduced injuries;
- durable fat loss or better metabolic health;
- improved sleep, cognition or longevity;
- safety with long-term exposure or combination use.
A phase 2 study in people with HIV-associated visceral obesity was registered as NCT00267527 and later marked terminated, with no results posted. It cannot be used as evidence of efficacy.
Why a higher GH or IGF-1 result is not a clinical outcome
Growth hormone and IGF-1 are active throughout metabolism, tissue growth and fluid regulation. Raising them confirms target engagement, but the direction and clinical value depend on the patient. The same pathway can influence glucose handling, edema, joint symptoms and growth-related processes.
For a genuine endocrine disorder, diagnosis is based on clinical context and validated testing, not a desire to raise a single laboratory value. FDA's CJC-1295 review found no human effectiveness studies in patients with growth hormone deficiency and pointed to approved therapies with characterized labeling for that condition.
This is a recurring issue across the growth-hormone peptide group. Biomarker activity should be described as pharmacodynamic evidence, not proof of recovery or anti-aging.
Safety signals and evidence gaps
The original journal report described no serious adverse reactions in its short, small studies. FDA's later review examined more detailed exposure information and found that injection-site reactions were common. Reported events included flushing, warmth, transient low blood pressure, headache, nausea, abdominal symptoms, dizziness, involuntary leg contractions, coordination changes and a dose-related increase in heart rate.
FDA also highlights possible immunogenicity, aggregation, peptide-related impurities and active-ingredient characterization problems in compounded CJC-1295. The agency's review found only 63 exposed healthy participants in the main published studies; most were men, most received a single exposure and no pediatric safety data were available. That is far too little to define long-term risk.
The prolonged action creates an additional practical concern: once exposure occurs, an unwanted endocrine or cardiovascular effect cannot be treated as if it came from a very short-lived peptide. Claims that the compound merely "supports natural release" understate its engineered duration.
Approval, Thailand and sports status
CJC-1295 is not an FDA-approved drug. FDA's December 2024 advisory review recommended against adding the evaluated CJC-1295 forms to the US 503A compounding bulks list, citing inadequate characterization, safety concerns and insufficient effectiveness evidence. That process is separate from Thai regulation, but it provides a detailed evidence assessment.
In Thailand, confirm the exact finished product through the Thai FDA medicine search. Ask a licensed professional to verify the active form, manufacturer and approved indication. A clinic offering or import listing does not replace product registration.
The 2026 WADA Prohibited List prohibits GHRH analogues and growth hormone-releasing factors at all times. Athletes should treat CJC-1295 as prohibited regardless of DAC wording.
A practical CJC-1295 claim-check
Before accepting a benefit claim, document:
- Exact identity: DAC or non-DAC, free base or salt, and verified sequence.
- Population: healthy volunteers or patients with the claimed diagnosis.
- Outcome: hormone concentration or a meaningful functional endpoint.
- Duration: short exposure study or adequate long-term follow-up.
- Comparator: placebo, established treatment or no control.
- Product status: an approved finished medicine or an unapproved preparation.
If the evidence comes from healthy volunteers given CJC-1295 DAC but the advertised product is an unnamed no-DAC blend, both the molecule and the clinical question have changed.
Common mistakes when comparing CJC-1295
- Treating all commercial names as synonyms. The DAC group changes pharmacokinetics.
- Calling elevated IGF-1 a proven benefit. It is a surrogate marker with potential risks as well as effects.
- Borrowing tesamorelin's approval. Tesamorelin has its own product-specific evidence and narrow indication.
- Assuming combination use is validated. Pairing CJC-1295 with a ghrelin mimetic has not been shown to deliver better patient outcomes.
- Ignoring study demographics. The main safety exposure was small, short and predominantly male.
Frequently asked questions
Is CJC-1295 the same as CJC-1295 without DAC?
No reliable assumption can be made from those labels alone. Published human research primarily concerns a long-acting DAC form, while sellers use CJC-1295 and no-DAC terminology inconsistently for chemically different materials.
Has CJC-1295 been proven to treat growth hormone deficiency?
No. Small trials showed sustained GH and IGF-1 increases in healthy adults, but FDA's review found no human effectiveness evidence for CJC-1295 in patients with growth hormone deficiency.
Is CJC-1295 allowed in tested sport?
No. WADA prohibits growth hormone-releasing factors, their analogues and growth hormone secretagogues at all times, which covers CJC-1295.
Bottom line
CJC-1295 DAC has clear, long-lasting pharmacodynamic activity in small healthy-volunteer studies. That is not the same as proven treatment benefit, established chronic safety or evidence for products sold under inconsistent no-DAC labels. A useful next step is to clarify the medical question with an endocrinologist and compare the actual evidence with the historical profile of sermorelin and the approved, indication-specific evidence for tesamorelin.